20 articles
Italian researchers developed a biosensor to track extracellular vesicles in blood, potentially personalizing stroke rehabilitation.
Duke University study tests whether targeted brain stimulation can reverse age-related cognitive decline and improve working memory.
Large 503-patient study tested whether Actovegin could improve thinking and memory problems that persist after stroke recovery.
Small trial tests electrical brain stimulation to improve sleep quality and cognitive function in patients with vascular dementia.
Clinical trial explores how targeted light treatment could restore circadian rhythms and improve brain function in mild cognitive impairment.
Personalized treatment approach targeting multiple causes of cognitive decline outperformed standard care in 9-month trial.
A pilot trial tests whether group and phone-based CBT can sharpen cognition and cut chronic stress in African Americans at risk for Alzheimer's.
NGP 555 targets toxic brain protein production in healthy volunteers, offering potential early intervention for Alzheimer's prevention.
A completed Mount Sinai RCT tested whether HBOT can improve brain blood flow and cognition in diabetic elders with mild cognitive impairment.
Clinical trial explores whether resetting gut microbiome through fecal transplants can slow Parkinson's progression and reduce symptoms.
A 210-person trial tests whether 5-month music therapy programs — and robotic assistants — can slow cognitive decline in older adults.
A Phase 4 RCT tests whether one bevacizumab injection matches two combined doses for neovascular AMD outcomes over 12 months.
TONTT2 tests whether erythropoietin dose and timing can be optimized to best preserve vision after traumatic optic neuropathy.
A completed Phase 1/2 pilot trial tested whether the senolytic duo D+Q penetrates the brain in early Alzheimer's disease.
A double-blind trial tests whether 810nm photobiomodulation can reverse cognitive impairment in long COVID patients at home.
Study tests VR therapy versus traditional cognitive training in 60 patients with mild cognitive impairment and Alzheimer's disease.
Individualized brain training targets specific cognitive weaknesses in adults over 50 with HIV-associated thinking problems.
Researchers at Duke University tested a blood-based biomarker to stratify Alzheimer's patients from healthy adults, aiming to enable earlier detection.
A Phase 2 open-label trial explores whether an approved immune drug can raise frataxin protein levels and slow neurological decline in Friedreich Ataxia.
A completed University of Kansas trial investigates whether creatine monohydrate can support brain energy metabolism in Alzheimer's patients.
